EOS Med Chem produce Linifanib(ABT-869),796967-16-3, assay 99.2% to be China biggest, NMR, MS, COA is OK.
Name: Linifanib (ABT-869)
CAS#: 796967-16-3
Chemical Formula: C21H18FN5O
Exact Mass: 375.14954
Molecular Weight: 375.4
Elemental Analysis: C, 67.19; H, 4.83; F, 5.06; N, 18.66; O, 4.26
Synonym: ABT869; ABT 869; ABT-869; Linifanib
IUPAC/Chemical Name: N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N1-(2-fluoro-5-methylphenyl) urea
InChi Key: ACPCMBPQKQTAQY-UHFFFAOYSA-N
InChi Code: InChI=1S/C21H18FN5O/c1-12-5-10-16(22)18(11-12)27(21(24)28)14-8-6-13(7-9-14)15-3-2-4-17-19(15)20(23)26-25-17/h2-11H,1H3,(H2,24,28)(H3,23,25,26)
SMILES Code: O=C(N)N(C1=CC=C(C2=CC=CC3=C2C(N)=NN3)C=C1)C4=CC(C)=CC=C4F
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Safety Data Sheet (MSDS): View Material Safety Data Sheet (MSDS)
2017 China CPHI: E1M35
EOS Med Chem, Medchem is Big
執大象，天下往，往而無害，安平泰
労働時間: Beijing Time 4:00AM~11:00PM
郵箱: info@eosmedchem.com ; eosmedchem@gmail.com
辦公室: 0086-531-69905422-806(直通)
攜帶番號 & WhatsApp & Wechat: +8618653174435
住所: Diaozhen Chemical Industrial Park, Jinan City, China
Skype: willgutian
QQ: 2393923585
|
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: soluble in DMSO, not soluble in water.
Shelf Life: >5 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. Linifanib demonstrated clinically meaningful activity in patients with advanced RCC after sunitinib failure. At 0.25 mg/kg/day, significant dose modifications were required. An alternative, fixed-dosing strategy is being evaluated in other trials. (source: Eur J Cancer. 2011 Dec;47(18):2706-14 ).
Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. Linifanib demonstrated clinically meaningful activity in patients with advanced RCC after sunitinib failure. At 0.25 mg/kg/day, significant dose modifications were required. An alternative, fixed-dosing strategy is being evaluated in other trials. (source: Eur J Cancer. 2011 Dec;47(18):2706-14 ).
Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer. Linifanib is active in advanced non-small cell lung cancer as second- or third-line therapy. Increased adverse event rates were observed at the high dose of linifanib . (source: J Thorac Oncol. 2011 Aug;6(8):1418-25. ).
Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer.
(source: J Thorac Oncol. 2011 Aug;6(8):1418-25. ).
